References
- Stein H, Mason D Y, Gerdes J, O'Connor N, Wainscoat J, Pallesen G, et al. The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplasmtic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood 1985; 66: 848–858
- Delsol G, Rallfkiaer E, Stein H, Wright D, Jaffe E S. Anaplastic large cell lymphoma. Jaffe ES. Stein H, Vardiman JW, editors. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, Harris NL 2001; 230–235, Lyon: IARC Press
- Reiter A, Schrappe M, Tiemann M, Parwaresch R, Zimmermann M, et al. Successful treatment strategy for Ki-1 anaplastic large-cell lymphoma of childhood: a prospective analysis of 62 patients enrolled in three consecutive Berlin-Frankfurt-Munster group studies. J Clin Oncol 1994; 12: 899–908
- Seidemann K, Tiemann M, Schrappe M, Yakisan E, Simonitsch I, Janka-Schaub G, et al. Short-pulse B-non-Hodgkin Lymphoma-type chemotherapy is efficacious treatment for pediatric anaplastic large cell lymphoma: a report of the Berlin-Frankfurt – Munster Group Trial NHL-BFM 90. Blood 2001; 97: 3699–3706
- Brugieres L, Le Deley M C, Pacquement H, Meguerian-Bedoyan Z, Terrier-Lacombe M J, et al. CD30anaplastic large-cell lymphoma in children: analysis of 82 patients enrolled in two consecutive studies of the French society of pediatric oncology. Blood 1998; 92: 3591–3598
- Williams D M, Hobson R, Imeson J, Gerrard M, McCarthy K, Pinkerton C R. Anaplastic large cell lymphoma in childhood: analysis of 72 patient treated on United Kingdom Children's Cancer Study Group chemotherapy regimens. Br J Haematol 2002; 117: 812–820
- Massimino M, Gasparini M, Giardini R. Ki-1 (CD30) anaplastic large-cell lymphoma in children. Ann Oncol 1995; 6: 915–920
- Morris S W, Kirstein M N, Valentine M B, Dittmer K G, Shapiro D N, Saltman D L, Look A T. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma. Science 1994; 263: 1281–1284
- Falini B, Pileri S, Zinzani P L, Carbone A, Zagonel V, Wolf-Peeters C, et al. ALK + Lymphoma: Clinicopathological findings and outcome. Blood 1999; 93: 2697–2706
- Drexler H G. The leukemia-lymphoma cell line facts book. Academic Press, London 2000
- Drexler H G, MacLeod R AF. Malignant hematopoietic cell lines. Leukemia. 2004; 18: 1569–1571, In vitro models for the study of anaplastic large-cell lymphoma
- Drexler H G, Gignac S M, Dirks W G, von Wasielewski R, Werner M. Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 2000; 14: 1533–1559
- Chen C L, Fuscoe J C, Liu Q, Pui C -H. Relationship between cytotoxicity and site-specific DNA recombination after in vitro exposure of leukemia cells to etoposide. J Natl Cancer Inst 1996; 88: 1840–1847
- Hijiya N, Gajjar A, Zhang Z, Sandlund J T, Ribeiro R C, Rubnitz J E, et al. Low-dose oral etoposide-based induction regimen for children with acute lymphoblastic leukemia in first bone marrow relapse. Leukemia 2004; 18: 1581–1586
- Fan M, Goodwin M E, Birrer M J, Chambers T C. The c-Jun NH 2-terminal protein kinase/AP-1 pathway is required for efficient apoptosis induced by vinblastine. Cancer Res 2001; 61: 4450–4458
- Brugieres L, Quartier P, Le Delay M C, Pacquement H, Perel Y, Bergeron C, et al. Relapse of childhood anaplastic large-cell lymphoma: Treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000; 11: 53–58